Journal of Internal Medicine Concepts & Practice ›› 2022, Vol. 17 ›› Issue (06): 471-474.doi: 10.16138/j.1673-6087.2022.06.010
• Review article • Previous Articles Next Articles
QIAN Lan, WU Tao(
)
Received:2021-09-13
Online:2022-12-30
Published:2023-02-27
CLC Number:
QIAN Lan, WU Tao. Progress of research on Niemann-Pick disease type A and type B[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 471-474.
| [1] |
Niemann-Pick disease: own observations and new therapeutic options[J]. Orv Hetil, 2021, 162(2): 74-80.
doi: 10.1556/650.2021.31950 URL |
| [2] |
Wheeler S, Sillence DJ. Niemann-Pick type C disease: cellular pathology and pharmacotherapy[J]. J Neurochem, 2020, 153(6): 674-692.
doi: 10.1111/jnc.14895 pmid: 31608980 |
| [3] |
McGovern MM, Wasserstein MP, Bembi B, et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation[J]. Orphanet J Rare Dis, 2021, 16(1): 212.
doi: 10.1186/s13023-021-01842-0 pmid: 33971920 |
| [4] |
Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease[J]. Mol Genet Metab, 2017, 120(1-2): 27-33.
doi: S1096-7192(16)30317-1 pmid: 28164782 |
| [5] |
Zampieri S, Filocamo M, Pianta A, et al. SMPD1 mutation update: database and comprehensive analysis of published and novel variants[J]. Hum Mutat, 2016, 37(2): 139-147.
doi: 10.1002/humu.22923 pmid: 26499107 |
| [6] |
Alcalay RN, Mallett V, Vanderperre B, et al. SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson’s disease[J]. Mov Disord, 2019, 34(4): 526-535.
doi: 10.1002/mds.27642 URL |
| [7] |
Ordieres-Ortega L, Galeano-Valle F, Mallén-Pérez M, et al. Niemann-Pick disease type-B: a unique case report with compound heterozygosity and complicated lipid management[J]. BMC Med Genet, 2020, 21(1): 1-6.
doi: 10.1186/s12881-019-0942-4 URL |
| [8] |
Pinto C, Sousa D, Ghilas V, et al. Acid sphingomyelinase deficiency[J]. Int J Mol Sci, 2021, 22(23): 12870.
doi: 10.3390/ijms222312870 URL |
| [9] | Thurberg BL. Autopsy pathology of infantile neurovisceral ASMD (Niemann-Pick disease type A)[J]. Mol Genet Metab Rep, 2020, 24: 100626. |
| [10] |
Moles A, Tarrats N, Fernández-Checa JC, et al. Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease[J]. J Biol Chem, 2012, 287(2):1178-1188.
doi: 10.1074/jbc.M111.272393 pmid: 22102288 |
| [11] |
Dhami R, He X, Gordon RE, et al. Analysis of the lung pathology and alveolar macrophage function in the acid sphingomyelinase[J]. Lab Invest, 2001, 81(7): 987-999.
pmid: 11454988 |
| [12] |
Cerón-Rodríguez M, Vázquez-Martínez ER, García-Delgado C, et al. Niemann-Pick disease A or B in four pediatric patients and SMPD1 mutation carrier frequency in the Mexican population[J]. Ann Hepatol, 2019, 18(4): 613-619.
doi: S1665-2681(19)30056-0 pmid: 31122880 |
| [13] | Cox GF, Clarke LA, Giugliani R, et al. Burden of illness in acid sphingomyelinase deficiency[J]. JIMD Rep, 2018, 41: 119-129. |
| [14] |
Al-Eitan L, Alqa’qa’ K, Amayreh W, et al. Novel mutations in the SMPD1 gene in Jordanian children with acid sphingomyelinase deficiency (Niemann-Pick types A and B)[J]. Gene, 2020, 747: 144683.
doi: 10.1016/j.gene.2020.144683 URL |
| [15] |
McGovern MM, Dionisi-Vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency[J]. Genet Med, 2017, 19(9): 967-974.
doi: 10.1038/gim.2017.7 pmid: 28406489 |
| [16] |
Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant)[J]. Mol Genet Metab, 2016, 118(3): 206-213.
doi: 10.1016/j.ymgme.2016.05.001 pmid: 27198631 |
| [17] |
McGovern MM, Avetisyan R, Sanson BJ, et al. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency(ASMD)[J]. Orphanet J Rare Dis, 2017, 12(1):41.
doi: 10.1186/s13023-017-0572-x URL |
| [18] |
Wasserstein M, Godbold J, McGovern MM. Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B[J]. J Inherit Metab Dis, 2013, 36(1): 123-127.
doi: 10.1007/s10545-012-9503-0 pmid: 22718274 |
| [19] | 徐威, 翟允鹏, 常宏, 等. 脾切除治疗成人型尼曼-匹克病1例[J]. 中国现代普通外科进展, 2014, 17(1): 81-82. |
| [20] |
Lipiński P, Kuchar L, Zakharova EY, et al. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients[J]. Orphanet J Rare Dis, 2019, 14(1):55.
doi: 10.1186/s13023-019-1029-1 pmid: 30795770 |
| [21] |
Bender CV, da Silveira HLD, Dos Santos NS, et al. Oral, dental, and craniofacial features in chronic acid sphingomyelinase deficiency[J]. Am J Med Genet A, 2020, 182(12): 2891-2901.
doi: 10.1002/ajmg.a.61871 URL |
| [22] |
Jones SA, McGovern M, Lidove O, et al. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy[J]. Mol Genet Metab, 2020, 131(1-2): 116-123.
doi: 10.1016/j.ymgme.2020.06.008 pmid: 32616389 |
| [23] |
Liu Y, Luo Y, Xia L, et al. The effects of liver transplantation in children with Niemann-Pick disease type B.[J]. Liver Transpl, 2019, 25(8): 1233-1240.
doi: 10.1002/lt.25457 URL |
| [24] | 陈姣, 刘小梅, 肖娟, 等. 异基因造血干细胞移植治疗尼曼匹克病B型1例[J]. 中国小儿血液与肿瘤杂志, 2021, 26(1): 48-50. |
| [25] | Quarello P, Spada M, Porta F, et al. Hematopoietic stem cell transplantation in Niemann-Pick disease type B monitored by chitotriosidase activity[J]. Pediatr Blood Cancer, 2018, 65(2): 10. |
| [26] |
Mercati O, Pichard S, Ouachée M, et al. Limited benefits of presymptomatic cord blood transplantation in neurovisceral acid sphingomyelinase deficiency (ASMD) intermediate type[J]. Eur J Paediatr Neurol, 2017, 21(6): 907-911.
doi: 10.1016/j.ejpn.2017.07.015 URL |
| [27] |
McGovern MM, Wasserstein MP, Kirmse B, et al. Novel first-dose adverse drug reactions during a phase Ⅰ trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency)[J]. Genet Med, 2016, 18(1): 34-40.
doi: 10.1038/gim.2015.24 URL |
| [28] |
Wasserstein MP, Jones SA, Soran H, et al. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency[J]. Mol Genet Metab, 2015, 116 (1-2): 88-97.
doi: 10.1016/j.ymgme.2015.05.013 pmid: 26049896 |
| [29] |
Wasserstein MP, Diaz GA, Lachmann RH, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD)[J]. J Inherit Metab Dis, 2018, 41(5): 829-838.
doi: 10.1007/s10545-017-0123-6 pmid: 29305734 |
| [30] |
Thurberg BL, Diaz GA, Lachmann RH, et al. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency(ASMD)[J]. Mol Genet Metab, 2020, 131(1-2): 245-252.
doi: 10.1016/j.ymgme.2020.06.010 pmid: 32620536 |
| [31] |
Garnacho C, Dhami R, Solomon M, et al. Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-Pick disease mice[J]. Mol Ther, 2017, 25(7): 1686-1696.
doi: S1525-0016(17)30232-0 pmid: 28606376 |
| [32] |
Hughes MP, Smith DA, Morris L, et al. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease[J]. Hum Mol Genet, 2018, 27(17): 3079-3098.
doi: 10.1093/hmg/ddy212 pmid: 29878115 |
| [33] |
Samaranch L, Pérez-Cañamás A, Soto-Huelin B, et al. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A[J]. Sci Transl Med, 2019, 11(506): eaat3738.
doi: 10.1126/scitranslmed.aat3738 URL |
| [34] |
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system[J]. Int J Mol Sci, 2018, 19(3): 833.
doi: 10.3390/ijms19030833 URL |
| [35] | Bartoll A, Toledano-Zaragoza A, Casas J, et al. Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling[J]. EMBO Mol Med, 2020, 12(11): e11776. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
